Literature DB >> 26700664

Akt activation correlates with the tumor aggressiveness in Tunisian patients with bladder cancer.

Islem Ben Bahria-Sediki1,2,3, Carla Sampaio1,2, Mohamed Chebil4, Mohamed Cherif4, Rachida Zermani4, Soumaya Rammeh4, Amel Ben Ammar El Gaaied5, Ali Bettaieb6,7.   

Abstract

Various studies in western countries found Akt amplification to be a frequent event in human cancers, including bladder, but the correlation with clinicopathological features is controversial. Such studies have not been reported in African populations, including Tunisians. The purpose of this study was to assess expression of the phosphorylated/activated forms of Akt in tumors from Tunisian patients with bladder cancer and to correlate its expression with pathological and clinical parameters of the disease. The study included 72 patients of whom 34 were diagnosed as low- to medium-grade and 35 as high-grade; 30 were muscle stage and 39 non-muscle stage. Primary tumors from these patients, normal adjacent tissues, or bladder cancer cell-lines were analyzed for Ser473 phosphorylated Akt expression by Western blot. Seventy-two percent of primary tumors from patients with bladder cancer had increased levels of p-Akt. The p-Akt levels in patients with high-grade bladder cancer were significantly elevated compared to patients with low- or medium-grade bladder cancer. In invasive carcinoma, the p-Akt level was significantly higher than in superficial non-invasive bladder tumors. Concerning the influence of tobacco on Akt activation, no significant differences of p-Akt expression were found between non-smoker and smoker patients. Altogether, our results suggest that Akt activation can provide useful prognostic information and that tobacco represents a serious risk factor for recurrence in a cohort of Tunisian patients.

Entities:  

Keywords:  Akt; Bladder carcinoma; Prognosis; Tobacco

Mesh:

Substances:

Year:  2015        PMID: 26700664     DOI: 10.1007/s13277-015-4678-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  7 in total

1.  Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.

Authors:  Chih-Hao Sun; Yen-Hwa Chang; Chin-Chen Pan
Journal:  Histopathology       Date:  2011-06       Impact factor: 5.087

2.  Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.

Authors:  J Q Cheng; B Ruggeri; W M Klein; G Sonoda; D A Altomare; D K Watson; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

Review 3.  Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer.

Authors:  I Kausch; A Böhle
Journal:  Eur Urol       Date:  2002-01       Impact factor: 20.096

Review 4.  PI3K-Akt pathway: its functions and alterations in human cancer.

Authors:  M Osaki; M Oshimura; H Ito
Journal:  Apoptosis       Date:  2004-11       Impact factor: 4.677

Review 5.  Indole-3-carbinol and prostate cancer.

Authors:  Fazlul H Sarkar; Yiwei Li
Journal:  J Nutr       Date:  2004-12       Impact factor: 4.798

6.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

Authors:  J Q Cheng; A K Godwin; A Bellacosa; T Taguchi; T F Franke; T C Hamilton; P N Tsichlis; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

Review 7.  Bladder cancer.

Authors:  Donald S Kaufman; William U Shipley; Adam S Feldman
Journal:  Lancet       Date:  2009-06-10       Impact factor: 79.321

  7 in total
  1 in total

1.  Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer.

Authors:  Junmi Lu; Hongjing Zang; Hongmei Zheng; Yuting Zhan; Yang Yang; Yuting Zhang; Sile Liu; Juan Feng; Qiuyuan Wen; Mengping Long; Songqing Fan
Journal:  PLoS One       Date:  2020-02-05       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.